The BioHub: The Top Voices in Biotech

We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies.Throughout his career, he has played a pivotal role in advancing innovative therapies from early discovery through to global commercialization. At Causeway Therapeutics, he is leading the charge in developing breakthrough treatments aimed at addressing serious and underserved medical needs.In this we discuss:Entrepreneurship and building a biotech having spent decades in PharmaCauseway's recent encouraging clinic results and what makes there approach different to what's out there alreadyHow Causeway are thinking about the pipeline and upcoming milestones

In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture.Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify.We talk about starting companies from zero, building the right teams early, de-risking new ventures, and the realities of fundraising in today’s biotech market. A practical, honest conversation with a true biotech builder.

We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs.Over the years, Simeon has helped build and back some of the most impactful companies in modern biotech, including CRISPR Therapeutics, Turning Point Therapeutics, and Principia Biopharma, among many others. He’s also a co-founder and board member of multiple biotech companies, working closely with scientists and founders to bring new medicines to patients

Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent.Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial services, holding senior HR leadership roles at organizations like the Broad Institute of MIT and Harvard, Warp Drive Bio, Aegerion Pharmaceuticals, and several major financial institutions.In this we discuss:Kim's 8.5 year journey so far at Fulcrum, from a small, ambitious biotech to the more mature, resilient organization it is today.Restructuring and the lessons learnt about leadership,communication, and empathy during times of crisisKim's new book 'The Culture Shock'

In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics.Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies.We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset, leadership, and what it really takes to build in small biotech.

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.In this we cover: The spark that led to the founding of Enara BioEnara's platform EDAPT® and how it finds dark antigens in tumors.Where the field of T-Cell therapy for solid tumors is today.The importance of culture in early stage biotech, and how the company has been built around putting people first.The next major milestones for Enara Bio.

JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon BioIn this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer, CEO and Founder of Hexagon Bio.Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform company in today’s market — from scientific conviction and capital discipline to leadership, culture, and long-term vision.We also discuss:What makes Hexagon’s approach fundamentally differentHow Maureen thinks about risk, focus, and scale as a founder-CEOThe realities of building biotech through multiple market cyclesA thoughtful, grounded conversation with one of the most impressive founders in the space.

I’m here with Mike Exton, the CEO of LexiconPharmaceuticals.Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto.Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need.Mike, great to have you here

In our first JPM Special 2026, we’re joined by Dirk Thye, CEO of Quince Therapeutics, as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech.

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early discovery to clinical development. At Delphia Therapeutics, Kevin is leading the development of a new approach to precision oncology known as activation lethality—an emerging strategy designed to uncover previously untapped cancer vulnerabilities and deliver more targeted, effective treatments. With a background that blends rigorous science, entrepreneurial leadership, and a patient-first mindset, Kevin brings a thoughtful perspective on the future of cancer therapy, innovation in biotech, and what it truly takes to build a science-driven company from the ground up. We’re excited to have him with us today.

Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases.With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs.Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.

We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio, a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub!Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag Bio, he heldsenior executive roles at several innovative life-science companies, including bluebird bio, where he served in multiple leadership positions across strategy, operations, finance, and legal affairs. He has also led and advised emerging biotech companies as both a CEO and board member.At Zag Bio, Jason is leading a bold effort to rethinkhow autoimmune diseases are treated. Their work aims to address the root cause of autoimmunity, with the potential for more durable and transformative therapies.We’re excited to talk with Jason today about his careerjourney, the science behind Zag Bio, and what it takes to build the next generation of biotech innovation.

Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences.Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia. Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies.In this conversation, we get into what inspired him to join Pacira, how the company has evolved, and how they’ve aligned the entire organization around a clear and bold mission. We also dive into leadership, culture, and the future of pain management.Let’s get into it.

Welcome to The BioHub Podcast.I’m joined by Luba Greenwood, CEO of Gallop.Luba’s one of the most respected voices in biotech — a three-time CEO, founder of Binney Street Capital at Dana-Farber, and a driving force behind Biotech Hangout.We talk about Gallop’s mission, what it takes to build strong culture in tough markets, and the personal motivation behind her work after losing her mum to cancer.It’s an inspiring and powerful conversation — let’s get intoit.

Today we’re joined by a leader at the forefront of next-generation immunotherapy — Dr. Christian Leisner. Christian is the CEO and co-founder of CDR-Life, a biotechnology company pioneering a new class of highly targeted T-cell engaging therapies designed to tackle some of the most difficult-to-treat cancers.With a PhD in Biochemistry from ETH Zurich and a Master’s in Molecular Biology and Chemistry from Roskilde University in Denmark, Christian has built a career that bridges deep scientific expertise with strategic leadership. Before launching CDR-Life, he held key roles at Novartis, Alcon, and the biotech success story ESBATech, contributing to global development programs across oncology, ophthalmology, autoimmunity, and cardiovascular disease.Today, Christian leads CDR-Life’s mission to unlock the potential of MHC-targeted immunotherapies — developing treatments designed to precisely attack tumor cells by recognizing intracellular antigens, long thought to be ‘undruggable.’ Under his leadership, the company is shaping what could become a transformational approach in the fight against cancer.We’re thrilled to have him with us today to explore the science, the strategy, and the future of immunotherapy

We were delighted to welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub! Avacta are a clinical-stage biotech pioneering next-generation oncology therapies.With a remarkable career spanning top pharmaceutical companies and cutting-edge biotech — from Immunocore and Rubius Therapeutics to Tmunity and CytoImmune — Christina brings a unique blend of medical expertise, scientific insight, and leadership acumen. At Avacta, she is driving the development of groundbreaking therapeutics, leveraging proprietary platforms like pre|CISION™, with the goal of bringing life-changing treatments from lab to clinic.In this episode, we’ll explore her journey from clinician-scientist to biotech executive, the vision and science behind Avacta, and the challenges and opportunities in developing innovative cancer therapies in today’s evolving regulatory and commercial landscape.

Welcome to another Episode of The BiohubToday, I’m joined by Jill Howe, Chief Financial Officer at Lineage Cell Therapeutics, a company developing groundbreaking allogeneic cell therapies for conditions like dry AMD, spinal cord injury, and hearing loss.Jill’s career spans more than 20 years across some of biotech’s most successful companies, helping take both Receptos and Gossamer Bio public before stepping into her current role at Lineage.We talk about what inspired her to join the company, how shehelps shape and protect Lineage’s culture, what excites her most about their pipeline, and her perspective on leadership and women in biotech.Let’s get into it.

Welcome back to another episode of The BioHub, we were thrilled to introduce a guest whose career lies at the cutting edge of cell therapy, biotech leadership, and real-world impact. Abigail Jenkins is a visionary biotech CEO whose journey has taken her from pioneering the development of cell therapies to leading companies at the forefront of regenerative medicine.Before stepping into her current role, Abigail served as CEO of Gamida Cell, where she guided the company through pivotal stages of clinical development, advanced its pipeline of therapies, and championed innovation in cell-based treatments for patients in need. Her leadership helped bring new hope to people suffering from life-threatening diseases — all while navigating the complexities of regulatory approval, scientific uncertainty, and market pressures.

Today we’re joined by one of Europe’s most respected builders of biotechnology companies — Luc Dochez.Luc is a scientist-turned-entrepreneur whose career has helped shape the next generation of therapies in oncology, rare diseases, and genetic medicine. Over the past two decades, he has co-founded and led multiple biotech companies, including Vico Therapeutics, Montis Biosciences, and Pharvaris, and he served as CEO of Tusk Therapeutics, guiding it all the way to its acquisition by Roche.Before becoming a serial entrepreneur, Luc held senior leadership roles at Prosensa, TiGenix, and other pioneering biopharma firms, building a reputation for turning cutting-edge science into real therapeutic opportunities. Today, as a Managing Partner at DROIA Ventures, he invests in and mentors the startups pushing the boundaries of precision medicine.With a background that spans pharmacy, business strategy, company formation, and venture capital, Luc brings a uniquely holistic perspective on how breakthrough therapies go from idea to impact.

Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn.Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies.Now at CytoDyn, Robert is helping steer the company as itadvances its lead monoclonal antibody program.This conversation is about leadership, staying motivated inbiotech’s toughest cycles, and the big vision for CytoDyn’s future.